



I hereby certify that the correspondence is being deposited with the U.S. Postal Service with ~~certified~~ postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 28, 2005

Signature: 

(Harvey L. Cohen)

Docket No.:
CIMA 3.0-030 CONT CONT
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Pather et al.

Application No.: 09/661,693

Group Art Unit: 1616

Filed: September 14, 2000

Examiner: M. Lamm

For: SUBLINGUAL BUCCAL EFFERVESCENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each foreign and journal reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

The references identified in this IDS have not been cited in corresponding foreign applications, but have been cited in other patent applications owned by the assignee of the subject application, which other applications are directed to related technology.


07/06/2005 RFEKADU1 00000020 121095 09661693

03 FC:1806 180.00 DA

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: June 28, 2005

Respectfully submitted,

By 

Harvey L. Cohen


Registration No.: 28,365
LERNER, DAVID, LITTBENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant

LD-458\



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 28, 2005

Signature: 

(Harvey L. Cohen)

Docket No.:
CIMA 3.0-030 CONT CONT
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Pather et al.

Application No.: 09/661,693

Group Art Unit: 1616

Filed: September 14, 2000

Examiner: M. Lamm

For: SUBLINGUAL BUCCAL EFFERVESCENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our deposit account No. 12-1095.


Dated: June 28, 2005

Respectfully submitted,

By 
Harvey L. Cohen

Registration No.: 28,365
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant

LD-453\



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| | | | | Application Number | 09/661,693-Conf. #2096 |
| | | | | Filing Date | September 14, 2000 |
| | | | | First Named Inventor | S. Indiran Pather |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | M. Lamm |
| Sheet | 1 | of | 2 | Attorney Docket Number | CIMA 3.0-030 CONT CONT |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| AA | US-1,262,888 | | 04/1918 | Preble, W.P. et al. | |
| AB | US-3,577,490 | | 05/1971 | Welsh, T. L. et al. | |
| AC | US-3,888,976 | | 06/1975 | Milkv et al. | |
| AD | US-3,961,041 | | 06/1976 | Nishimura et al. | |
| AE | US-4,147,768 | | 04/1979 | Schaffer et al. | |
| AF | US-4,187,286 | | 02/1980 | MARCUS, B.J. | |
| AG | US-4,289,751 | | 09/1981 | Windheuser | |
| AH | US-4,503,031 | | 03/1985 | Glassman | |
| AI | US-4,599,342 | | 07/1986 | LAHANN, THOMAS R. | |
| AJ | US-4,671,953 | | 06/1987 | STANLEY ET AL. | |
| AK | US-4,756,710 | | 07-12-1988 | Bondi et al. | |
| AL | US-5,073,374 | | 12/1991 | MCCARTY, JOHN A. | |
| AM | US-5,468,504 | | 11/1995 | Schaeffer, Alain E. E. | |
| AN | US-5,503,846 | | 04-02-1996 | Wehling et al. | |
| AO | US-5,559,096 | | 09/1996 | Edwards et al. | |
| AP | US-5,624,687 | | 04-29-1997 | Yano et al. | |
| AQ | US-5,626,866 | | 05-06-1997 | Ebert et al. | |
| AR | US-5,646,151 | | 07/1997 | Kruse et al. | |
| AS | US-5,853,748 | | 12-29-1998 | New | |
| AT | US-5,900,252 | | 05-04-1999 | Calanchi et al. | |
| AU | US-5,952,004 | | 09-14-1999 | Rudnic et al. | |
| AV | US-6,034,085 | | 03-07-2000 | Joshi et al. | |
| AW | US-6,068,853 | | 05-30-2000 | Giannos et al. | |
| AX | US-6,129,906 | | 10/2000 | Steventon | |
| AY | US-6,200,604 | | 03-13-2001 | Pather et al. | |
| AZ | US-6,316,027-B1 | | 11-13-2001 | Clarke, Anthony et al. | |
| AA1 | US-6,350,470-B1 | | 02/2002 | Pather et al. | |
| AB1 | US-6,391,335 | | 05-21-2002 | Pather et al. | |
| AC1 | US-6,488,961 | | 12/2002 | ROBINSON ET AL. | |
| AD1 | US-6,509,036 | | 01-21-2003 | Pather et al. | |
| AE1 | US-6,576,250-B1 | | 06/2003 | Pather et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | |
| BA | EP-0 197 504-A1 | | 10-15-1986 | Bondi et al. | |
| BB | EP-0 354 973-B2 | | 02-21-1990 | Paradissis | |
| BC | EP-0361680-A2 | | 04/1990 | MICHELL | |
| BD | GB-2307857-A | | 06/1997 | LESLIE ET AL. | |
| BE | WO-95/27482-A1 | | 10/1995 | FREEMAN ET AL. | |
| BF | WO-95/34291-A1 | | 12-21-1995 | JENSEN LINE NOERGAARD | |
| BG | WO-97/17067-A1 | | 05-15-1997 | Somerset Pharmaceuticals Inc. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|



| | | | | | |
|--|---|----|---|------------------------|------------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 09/661,693-Conf. #2096 |
| (Use as many sheets as necessary) | | | | Filing Date | September 14, 2000 |
| Sheet | 2 | of | 2 | First Named Inventor | S. Indiran Pather |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | M. Lamm |
| | | | | Attorney Docket Number | CIMA 3.0-030 CONT CONT |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | ² |
| | CA | AMIGHI, K.; TIMMERMANS, J.; PUIGDEVALL, J.; BALTES, E.; MOËS, A., J.; Peroral Sustained-Release Film-Coated Pellets as a Means to Overcome Physicochemical and Biological Drug-Related Problems. I. In Vitro Development and Evaluation, Drug Development and Industrial Pharmacy, 1998, pp. 509-515, vol. 24, no. 6. | | | |
| | CB | BERKO, S.; REGDON JUN, G.; ERÖS, I.; Influence of pH Change on Drug Release from Rectal Suppositories, Die Pharmazie, April 2000, p.324, Vol. 55., Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn. | | | |
| | CC | GIANNOS, S.A.; DINH, S.M.; BERNER, B.; Temporally Controlled Drug Delivery Systems: Coupling of pH Oscillators with Membrane Diffusion, Journal of Pharmaceutical Sciences, May 1995, pp. 539-543, Vol. 84, No. 5. | | | |
| | CD | Nishimura et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa VI: Formulation of Effervescent Enteric-Coated Tablets" J. Pharm. Sci. 73(7):942-46 (1984). | | | |
| | CE | RANADE, V.V.; Drug Delivery Systems Part 5B. Oral Drug Delivery, The Journal of Clinical Pharmacology, Feb. 1991, pp. 98-115, Vol. 31. | | | |
| | CF | Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(3):261-65 (1980). | | | |
| | CG | Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa III: Influence of Dose on Pharmacokinetic Behavior of Levodopa in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(12):1374-78 (1980). | | | |
| | CH | Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs" J. Pharm. Sci. 70(10):1157-60 (1981). | | | |
| | CI | Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa IV: Possible Causes of Low Bioavailability of Oral Levodopa in Dogs" J. Pharm. Sci. 70(7):730-33 (1981). | | | |
| | CJ | SORASUCHART, W.; WARDROP, J.; AYERS, J.; Drug Release from Spray Layered and Coated Drug-Containing Beads: Effects of pH and Comparison of Different Dissolution Methods, Drug Development and Industrial Pharmacy, 1999, pp. 1093-1098, Vol. 25, No. 10 | | | |
| | CK | STREUBEL, A.; SIEPMANN, J.; DASHEVSKY, A.; BODMEIER, R.; pH-Independent Release of a Weakly Basic Drug from Water-Insoluble and -Soluble Matrix Tablets, Journal of Controlled Release, 2000, pp. 101-110, Vol. 67. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|